STOCK TITAN

Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences
Argus Session date unavailable
-2.23% session move Open Argus
Details

News Market Reaction – LXEO

The recorded move for LXEO in the trading session of this news was -2.23%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 8:15 AM PT in San Francisco, California.

The event will be webcast live under the News & Events tab in the Investors section of the Company’s website. A replay of the webcast will be available after the conclusion of the live presentation.

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.

Media Response:
Janine Bogris
(201) 245-6838
janine.bogris@canalecomm.com

Investor Response:
Laurence Watts
(619) 916-7620
laurence@gilmartinir.com


Keep reading